Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMM
What is the purpose of this study?
To find out the safety and efficacy of iberdomide with dexamethasone and daratumumab (IberDd) or bortezomib and dexamethasone (IberVd).
In this video:
Dr. Neils van de Donk discussed the safety and efficacy of the two triplet regimens in patients with relapsed/refractory multiple myeloma – 27 patients were assigned to IberDd and 23 were assigned to IberVd.
Triplet combinations consisting of iberdomide with dexamethasone and daratumumab or bortezomib and dexamethasone demonstrated favorable tolerability profiles and promising clinical activity in patients with heavily pretreated multiple myeloma.
ASH 2020: Abstract 724
Neils van de Donk, MD
Niels van de Donk, MD, PhD, is a Hematologist at the VU University Medical Center, Amsterdam, Netherlands.